Home・Elenco Azioni・BioNTech SE ADR

BioNTech SE ADR

Chiusa

SettoreSettore sanitario

90.78 -1.14

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

88.01

Massimo

93.55

Metriche Chiave
By Trading Economics
Entrata	-239M -541M
Vendite	-779M 120M
EPS	-1.95
Margine di Profitto	-450.381
Dipendenti	7,807
EBITDA	-383M -450M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+36.04% upside

Dividendi
By Acuity
Utili prossimi	3 nov 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-1.8B 23B
Apertura precedente	91.92
Chiusura precedente	90.78

BioNTech SE ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

4 ago 2026, 20:03 UTC

News

Social Media

BioNTech SE reported a widened second-quarter loss and lowered 2026 revenue guidance, contributing to shares trading lower since Monday's close.

3 ago 2026, 21:01 UTC

BioNTech SE shares are lower in after-market hours, showing little movement despite a broader market rally and investor optimism from lower oil prices.

31 lug 2026, 19:16 UTC

Correlated Moves

BioNTech SE shares are lower today, pressured by broader market sentiment and a decline in Moderna Inc. The stock remains below its 20-day moving average.

30 lug 2026, 21:01 UTC

BioNTech SE shares are trading lower in after-market hours, reversing earlier gains and reflecting notable volatility without any specific news to explain the movement.

29 lug 2026, 19:55 UTC

BioNTech SE shares are advancing during Wednesday's session, reaching a session high earlier today before pulling back slightly. No specific news was identified.

28 lug 2026, 19:16 UTC

BioNTech SE shares are advancing today, rebounding from earlier lows. The stock's resilience contrasts with declines in the Nikkei 225 Index.

27 lug 2026, 19:06 UTC

BioNTech SE shares are higher today amid positive market sentiment, reaching a peak earlier. No specific news has been identified to explain the movement.

24 lug 2026, 19:06 UTC

BioNTech SE shares are lower today, continuing a decline amid broader market pressure and a significant drop in crude oil prices.

22 lug 2026, 18:06 UTC

BioNTech SE shares are lower today, reflecting broader market caution amid rising crude oil prices and geopolitical tensions ahead of major technology earnings reports.

21 lug 2026, 14:41 UTC

News

BioNTech SE is rising amid positive market sentiment and plans to report second-quarter 2026 results on August 4, 2026. The Nasdaq 100 Index is also up.

20 lug 2026, 19:06 UTC

News

BioNTech SE shares are higher today, supported by a positive analyst outlook and an average recommendation of "Moderate Buy" from nineteen brokerage firms.

Confronto tra pari

Modifica del prezzo

BioNTech SE ADR Previsione

Obiettivo di Prezzo

By TipRanks

36.04% in crescita

Previsioni per 12 mesi

Media 125.5 USD 36.04%

Alto 158 USD

Basso 94 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per BioNTech SE ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

12 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 12 che hanno fornito valutazioni azionarie a BioNTech SE ADR - Dist negli ultimi 3 mesi.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo BioNTech SE ADR

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac